NICE rejected Keytruda in patients with locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.
Sanofi and Regeneron's Dupixent could be on its way to €10 billion a year, but pushback from England's cost watchdog in severe asthma won't help.
Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term uncertainties.
After a draft report last November, ICER's final findings on Allergan and Biohaven migraine medicines are more favorable.
AbbVie is pinning high hopes—up to $20 billion—on new launches Rinvoq and Skyrizi. A cost-effectiveness nod could help Rinvoq reach that lofty goal.
NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.
Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.
Only weeks ago, Merck's I-O superstar Keytruda whiffed in a key lung cancer trial. Now the therapy is facing pushback from England's cost watchdog.
As JPM kicks into gear, Novartis CEO Vas Narasimhan and British health officials unveiled a new access agreement on inclisiran.
British cost watchdogs have rejected Akcea's Waylivra on cost-effectiveness concerns, but the company says it'll keep working with NICE.